The glutamate and dopamine hypotheses are leading theories of the pathoaetiology of
schizophrenia. Both were initially based on indirect evidence from pharmacological studies …

Abstract Treatment resistant schizophrenia (TRS) refers to the significant proportion of
schizophrenia patients who continue to have symptoms and poor outcomes despite …

Glutamate and dopamine systems play distinct roles in terms of neuronal signalling, yet both
have been proposed to contribute significantly to the pathophysiology of schizophrenia. In …

Economics and mental health are intertwined. Apart from the accumulating evidence of the
huge economic impacts of mental ill‐health, and the growing recognition of the effects that …

These updated guidelines are based on a first edition of the World Federation of Societies of
Biological Psychiatry Guidelines for Biological Treatment of Schizophrenia published in …

Mood and psychotic syndromes most often emerge during adolescence and young
adulthood, a period characterised by major physical and social change. Consequently, the …

The introduction of second-generation antipsychotics and cognitive therapies for
schizophrenia over the past two decades generated considerable optimism about …

Negative symptoms, eg social withdrawal, reduced initiative, anhedonia and affective
flattening, are notoriously difficult to treat. In this review, we take stock of recent research into …

These guidelines from the British Association for Psychopharmacology address the scope
and targets of pharmacological treatment for schizophrenia. A consensus meeting, involving …

Opinion Statement Interest in the negative symptoms of schizophrenia has increased rapidly
over the last several decades, paralleling a growing interest in functional, in addition to …